Slingshot members are tracking this event:

Novartis (NVS) to present full Phase 3 study data on RTH-258 treating Neurovascular Age-Related Macular Degeneration (AMD) at the American Academy of Ophthalmology Meeting on November 10th, 2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
NVS Community voting in process
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Rth-258, Phase 3 Topline Data